Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (38): 7066-7070.doi: 10.3969/j.issn.1673-8225.2011.38.009

Previous Articles     Next Articles

Intravascular biocompatibility of poly (3-hydroxybutyrate- co-3-hydroxyhexanoate)

Wu Song1, Liu Ying-long2, Tang Yue2, Wang Qiang2, Wan Feng1, Qu Xiang-hua3, Chen Guo-qiang3   

  1. 1Department of Cardiovascular Surgery, Peking University Third Hospital, Beijing  100191, China
    2Department of Cardiovascular Surgery, Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing  100037, China
    3Department of Biological Science and Biotechnology, Tsinghua University, Beijing  100084, China
  • Received:2011-03-01 Revised:2011-05-24 Online:2011-09-17 Published:2011-09-17
  • About author:Wu Song☆, Doctor, Attending physician, Department of Cardiovascular Surgery, Peking University Third Hospital, Beijing 100191, China drwusong@gmail.com

PDF

416

Abstract:

BACKGROUND: The degradable poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx) has superior mechanical property and biocompatibility.
OBJECTIVE: To elucidate the intravascular biocompatibility of PHBHHx in vivo.
METHODS: We developed hybrid materials based on decellularized xenogenic vascular scaffolds that were coated with PHBHHx and implanted it into the abdominal aorta of New Zealand rabbits. The decellularized xenogenic pulmonary artery patch without PHBHHx coating served as the control. The implanted patches were determined for the histology, immunofluorescence staining, scanning electron microscopy and calcium contents at 1, 4 and 12 weeks after the surgery.
RESULTS AND CONCLUSION: Hybrid patches exhibited smooth lumen surface without thrombus, the intimal hyperplasia was mild and recellularization was complete; immunofluorescence staining showed that the endothelial cells in the neointima were positive for CD31, with continuous single-layer arrangement, interstitial cells were positive for smooth muscle actin; the calcium content in hybrid patches was obviously lower than that in uncoated patches. PHBHHx shows a remarkable intravascular biocompatibility in vivo and is believed as an ideal candidate for lumen coating of cardiovascular tissue engineering.

CLC Number: